Poster Presenter
Bioactive Compounds From Glycyrrhiza Uralensis For Anti-Diabetic
Complications
HYO JIN KANG, SE JIN CHOI, YEON SIL LEE,
JEONG EUN KIM , IL-JUN KANG and SOON SUNG LIM
Republic of Korea
We evaluated the aldose reductase (AR) inhibitory
effect of Glycyrrhiza uralensis as part of our ongoing search
of natural sources for therapeutic and preventive agents for diabetic
complications. In order to identify the bioactive components of G.
uralensis, 5 prenylated flavonoids (semilicoisoflavone B, 7-O-methylluteone,
dehydroglyasperin C, dehydroglyasperin D, and isoangustone A), three
flavonoids (liquiritigenin, isoliquiritigenin, and licochalcone A),
and two triterpenoids (glycyrrhizin and glycyrrhetinic acid) were
isolated; their chemical structures were then elucidated on the basis
of spectroscopic evidence and comparison with published data. The
anti-diabetic complication activities of 10 G. uralensis-derived
components were investigated via inhibitory assays using rat lens
AR (rAR) and human recombinant AR (rhAR). From the 10 isolated compounds,
semilicoisoflavone B showed the most potent inhibition, with the IC50
values of rAR and rhAR at 1.8 and 10.6 μM, respectively. In the
kinetic analyses using Lineweaver-Burk plots of 1/velocity and 1/concentration
of substrate, semilicoisoflavone B showed noncompetitive inhibition
against rhAR. The results clearly indicated that the presence of a
γ,γ-dimethylchromene ring is partly responsible for the
AR inhibitory activity of isoprenoid-type flavonoids. Therefore, it
can be said that flavonoids from G. uralensis have potential
beneficial uses in the development of therapeutic and preventive agents
for diabetic complications
|
